Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 136 to 150 of 226 results for headache

  1. Insertion of an epiretinal prosthesis for retinitis pigmentosa (IPG519)

    Evidence-based recommendations on insertion of an epiretinal prosthesis for retinitis pigmentosa. This involves inserting an implant into the eye that receives data from a small camera on the person's glasses and then stimulates healthy cells in the retina to see basic images.

  2. Motor neurone disease: assessment and management (NG42)

    This guideline covers assessing and managing motor neurone disease (MND). It aims to improve care from the time of diagnosis, and covers information and support, organisation of care, managing symptoms and preparing for end of life care.

  3. Mitochondrial disorders in children: Co-enzyme Q10 (ES11)

    Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making

  4. Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza (TA158)

    Evidence-based recommendations on oseltamivir (Tamiflu), amantadine (Lysovir or Symmetrel) or zanamivir (Relenza) to prevent influenza (flu).

  5. Amantadine, oseltamivir and zanamivir for the treatment of influenza (TA168)

    Evidence-based recommendations on amantadine (Lysovir), oseltamivir (Tamiflu) and zanamivir (Relenza) for treating influenza in children and adults.

  6. Human growth hormone (somatropin) for the treatment of growth failure in children (TA188)

    Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humatrope, Norditropin, NutropinAq, Omnitrope, Saizen, Zomacton) for treating growth failure in children.

  7. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329)

    Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.

  8. Generalised anxiety disorder and panic disorder in adults: management (CG113)

    This guideline covers the care and treatment of people aged 18 and over with generalised anxiety disorder (chronic anxiety) or panic disorder (with or without agoraphobia or panic attacks). It aims to help people achieve complete relief of symptoms (remission), which is associated with better functioning and a lower likelihood of relapse.

  9. Everolimus for preventing organ rejection in liver transplantation (TA348)

    Evidence-based recommendations on everolimus (Certican) for preventing organ rejection in adults having a liver transplant.

  10. Transcervical extracorporeal reverse flow neuroprotection for reducing the risk of stroke during carotid artery stenting (IPG561)

    Evidence-based recommendations on transcervical extracorporeal reverse flow neuroprotection for reducing the risk of stroke during carotid artery stenting in adults. This involves reversing blood flow away from the brain and filtering the blood to remove any debris.

  11. Cerebral palsy in under 25s: assessment and management (NG62)

    This guideline covers diagnosing, assessing and managing cerebral palsy in children and young people from birth up to their 25th birthday. It aims to make sure they get the care and treatment they need for the developmental and clinical comorbidities associated with cerebral palsy, so that they can be as active and independent as possible.

  12. Gastro-oesophageal reflux in children and young people (QS112)

    This quality standard covers managing symptoms of reflux (regurgitation or bringing up feeds) in babies, children and young people (under 18). It also covers diagnosing and managing gastro-oesophageal reflux disease (also called GORD), which is more severe reflux and heartburn. It describes high-quality care in priority areas for improvement.

  13. Romiplostim for the treatment of chronic immune thrombocytopenia (TA221)

    Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune thrombocytopenia in adults.

  14. Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239)

    Evidence-based recommendations on fulvestrant (Faslodex), for treating locally advanced or metastatic breast cancer in adults.

  15. Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)

    Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and for preventing a further deep vein thrombosis or pulmonary embolism in adults.